Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients
a randomized double-blind placebo-controlled trial
Keywords:
Aspirin, Dipyridamole, Primary patency, Arteriovenous graftsAbstract
Background: There is some evidence for the efficacy of antiplatelet therapies in increasing the vascular access patency duration or decreasing the thrombosis of arteriovenous grafts. Objective: To determine the effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients Methods: This randomized, double-blind, placebo-controlled trial was done at Imam Reza Hospital in Mashhad, Iran from September 10, 2015 to July 05, 2016. Sixty hemodialysis patients, after the placement of a new arteriovenous graft, were divided into three study groups which including; Group 1, who received 80 mg aspirin tablet daily, Group 2 received 80 mg aspirin plus 75 mg dipyridamole daily and Group 3 received placebo daily. Primary unassisted patency was recorded in follow-up until 12 months and the outcomes were analysed using one-way ANOVA test. Results: Primary patency time in Group 1 (Aspirin) was 324.75±147.00 day and for Group 2 (Aspirin + Dipyridamole) was 399.05±92.09 day and for Group 3 (Placebo) was 383.55±108.23 day. There were no significant differences between the 3 groups (p>0.05). Successful dialysis was done in 16.7% in Group 1, 37.5% in Group 2 and 45% in Group 3 from brachial arteriovenous grafts after 1-year follow-up (p=0.746). Conclusions: In treating dialysis patients, treatment with low dose aspirin and dipyridamole is not effective on increasing the synthetic grafts primary patency duration. Trial registration: The trial was registered at the Thai Clinical Trials Registry (http://www.clinicaltrials.in.th) with the Trct id: TCTR20160920003. Funding: The authors received no financial support for the research, authorship, and/or publication of this article.References
Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, et al. Effect of dipyridamole plus
aspirin on hemodialysis graft patency. The New England journal of medicine. 2009; 360(21): 2191-201.
doi: 10.1056/NEJMoa0805840. PMID: 19458364, PMCID: PMC3929400.
Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D, et al. EBPG on Vascular Access.
Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant
Association - European Renal Association. 2007; 22 Suppl 2: ii88-117. doi: 10.1093/ndt/gfm021. PMID:
Bethesda M. U.S. Renal Data System 2006 Annual data report: atlas of end-stage renal disease in the
United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney
Diseases. 2006.
Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: a cellular and
molecular viewpoint. Journal of the American Society of Nephrology: JASN. 2006; 17(4): 1112-27. doi:
1681/ASN.2005050615. PMID: 16565259.
Gibson KD, Gillen DL, Caps MT, Kohler TR, Sherrard DJ, Stehman-Breen CO. Vascular access survival
and incidence of revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous
transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study.
Journal of vascular surgery. 2001; 34(4): 694-700. doi: 10.1067/mva.2001.117890. PMID: 11668326.
Lee T, Roy-Chaudhury P. Advances and new frontiers in the pathophysiology of venous neointimal
hyperplasia and dialysis access stenosis. Advances in chronic kidney disease. 2009; 16(5): 329-38. doi:
1053/j.ackd.2009.06.009. PMID: 19695501, PMCID: PMC2764321.
Tanner NC, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and
grafts. Cochrane Database Syst Rev. 2015; 7: CD002786. doi: 10.1002/14651858.CD002786.pub3. PMID:
Dixon BS, Beck GJ, Dember LM, Depner TA, Gassman JJ, Greene T, et al. Design of the Dialysis Access
Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial. Clinical trials. 2005; 2(5): 400-12. doi:
1191/1740774505cn110oa. PMID: 16317809.
Roy-Chaudhury P, Arend L, Zhang J, Krishnamoorthy M, Wang Y, Banerjee R, et al. Neointimal
hyperplasia in early arteriovenous fistula failure. American journal of kidney diseases. 2007; 50(5): 782-90.
doi: 10.1053/j.ajkd.2007.07.019. PMID: 17954291.
Roy-Chaudhury P, Kelly BS, Miller MA, Reaves A, Armstrong J, Nanayakkara N, et al. Venous neointimal
hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney international. 2001; 59(6): 2325-34. doi:
1046/j.1523-1755.2001.00750.x. PMID: 11380837.
Wang Y, Krishnamoorthy M, Banerjee R, Zhang J, Rudich S, Holland C, et al. Venous stenosis in a pig
arteriovenous fistula model--anatomy, mechanisms and cellular phenotypes. Nephrol Dial Transplant.
; 23(2): 525-33. doi: 10.1093/ndt/gfm547. PMID: 18037619.
Allon M. Current management of vascular access. Clin J Am Soc Nephrol. 2007; 2(4): 786-800. doi:
2215/CJN.00860207. PMID: 17699495.
Crowther MA, Clase CM, Margetts PJ, Julian J, Lambert K, Sneath D, et al. Low-intensity warfarin is
ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled
trial. J Am Soc Nephrol. 2002; 13(9): 2331-7. doi: 10.1097/01.ASN.0000027356.16598.99. PMID:
Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, et al. Randomized controlled trial
of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol. 2003;
(9): 2313-21. doi: 10.1097/01.ASN.0000081661.10246.33. PMID: 12937308.
Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a
prospective, randomized, double-blind study. Kidney international. 1994; 45(5): 1477-83. doi:
1038/ki.1994.192. PMID: 8072261.
Yevzlin AS, Conley EL, Sanchez RJ, Young HN, Becker BN. Vascular access outcomes and medication
use: a USRDS study. Semin dial. 2006; 19(6): 535-9. doi: 10.1111/j.1525-139X.2006.00218.x. PMID:
Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW, et al. Association between vascular
access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
American journal of kidney diseases. 2002; 40(6): 1255-63. doi: 10.1053/ajkd.2002.36895. PMID:
Harter HR, Burch JW, Majerus PW, Stanford N, Delmez JA, Anderson CB, et al. Prevention of thrombosis
in patients on hemodialysis by low-dose aspirin. The New England journal of medicine. 1979; 301(11):
-9. doi: 10.1056/NEJM197909133011103. PMID: 112475.
Hiremath S, Holden RM, Fergusson D, Zimmerman DL. Antiplatelet medications in hemodialysis patients:
a systematic review of bleeding rates. Clin J Am Soc Nephrol. 2009; 4(8): 1347-55. doi:
2215/CJN.00810209. PMID: 19578002, PMCID: PMC2723969.
Holden RM, Harman GJ, Wang M, Holland D, Day AG. Major bleeding in hemodialysis patients. Clin J
Am Soc Nephrol. 2008; 3(1): 105-10. doi: 10.2215/CJN.01810407. PMID: 18003768, PMCID:
PMC2390984.
Obialo CI, Conner AC, Lebon LF. Maintaining patency of tunneled hemodialysis catheters--efficacy of
aspirin compared to warfarin. Scandinavian journal of urology and nephrology. 2003; 37(2): 172-6. doi:
1080/00365590310008938. PMID: 12745728.
Ethier J, Bragg-Gresham JL, Piera L, Akizawa T, Asano Y, Mason N, et al. Aspirin prescription and
outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). American
journal of kidney diseases. 2007; 50(4): 602-11. doi: 10.1053/j.ajkd.2007.07.007. PMID: 17900460.
Wasse H, Gillen DL, Ball AM, Kestenbaum BR, Seliger SL, Sherrard D, et al. Risk factors for upper
gastrointestinal bleeding among end-stage renal disease patients. Kidney international. 2003; 64(4): 1455- 61. doi: 10.1046/j.1523-1755.2003.00225.x. PMID: 12969166.
Published
Issue
Section
License
Copyright (c) 2020 knowledge kingdom publishing
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
